News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Mochida Pharmaceuticals Completes Early Phase II Clinical Trial Of Epadel Indicated For Alzheimer’s Disease
December 15, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo (JCN) Dec 15, 2005 - Mochida Pharmaceutical has completed an early phase II clinical trial of Epadel, which is targeted at Alzheimer's disease. Epadel is the company's proprietary agent used in the treatment of hyperlipemia.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Asia
MORE ON THIS TOPIC
Huntington’s disease
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
September 29, 2026
·
4 min read
·
Heather McKenzie
Obesity
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
September 29, 2026
·
2 min read
·
Tristan Manalac
Business
Summit snags $2B investment from AstraZeneca, clearing financial overhang
September 29, 2026
·
3 min read
·
Tristan Manalac
China
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
September 29, 2026
·
2 min read
·
Annalee Armstrong
